ArticleThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2016
Agitation in Alzheimer Disease as a Qualifying Condition for Medical Marijuana in the United States.
Article in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 18 citations in OpenAlex.
- Agitation in Alzheimer's Disease as a Qualifying Condition for Medical Cannabis in the United States: A Brief Report on Current Trends.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2026Article
- The Therapeutic Potential of Psilocybin.Molecules (Basel, Switzerland) · 2021Review
- A Systematic Review of the Neurocognitive Effects of Cannabis Use in Older Adults.Current addiction reports · 2019Article
- The Use of Cannabinoids in Treating Dementia.Current neurology and neuroscience reports · 2017Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo determine the extent to which states and localities include dementia as a qualifying condition for medical marijuana and how common this indication is.
methodsThe authors reviewed authorizing legislation and medical marijuana program websites and annual reports for the states and localities where medical marijuana is legal.
resultsOf the 24 states and localities where medical marijuana is legal, dementia is a qualifying condition in 10 (41.7%), primarily for agitation of Alzheimer disease. In the five states where information was available regarding qualifying conditions for certification, dementia was the indication for <0.5% of medical marijuana certifications.
conclusionDementia is somewhat commonly listed as a potential qualifying condition for medical marijuana. Currently, few applicants for medical marijuana list dementia as the reason for seeking certification. However, given increasingly open attitudes toward recreational and medical marijuana use, providers should be aware that dementia is a potential indication for licensing, despite lack of evidence for its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.